SCHEMBL23319976

SCHEMBL23319976

O=C(O)c1nn[nH]c1Oc1ccc(Br)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 9/20 0.38
KMO O15229 2/20 0.36
LGALS8 O00214 1/20 0.36
LGALS3 P17931 1/20 0.36
CHRNA3 P32297 1/20 0.34
PRKAB2 O43741 4/20 0.34
PRKAG1 P54619 4/20 0.34
PRKAA2 P54646 4/20 0.34
PRKAA1 Q13131 4/20 0.34
PRKAG3 Q9UGI9 4/20 0.34
PRKAG2 Q9UGJ0 4/20 0.34
PRKAB1 Q9Y478 4/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799135 0.88 KMO (0.48) HAO1KMOLGALS8LGALS3LMNA
SCHEMBL21296869 0.88 KMO (0.48) HAO1KMOLGALS8LGALS3LMNA
SCHEMBL29799265 0.84 SOS1 (0.41) HAO1MAPTNPC1
SCHEMBL21296902 0.84 SOS1 (0.41) HAO1MAPTNPC1
SCHEMBL21296865 0.84 HAO1 (0.43) HAO1CHRNA3THRATHRBMAPT
SCHEMBL23319999 0.82 ALPL (0.43) HAO1PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL21296924 0.82 MCL1 (0.46) HAO1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21296971 0.82 HAO1 (0.41) HAO1KMO
SCHEMBL23319978 0.81 HAO1 (0.41) HAO1THRATHRBMAPTMEN1
SCHEMBL21312458 0.80 MCL1 (0.43) HAO1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS VENTHERA, INC. 2021-12-30 US disclosed
EP-3817816-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS Orfan Biotech Inc. (US) 2021-05-12 EP disclosed
CN-112399873-A Triazole glycolate oxidase inhibitor 奥凡生物科技公司 2021-02-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO HAO1 6/4885KMO 357/4885LGALS8 1648/4885
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO HAO1 6/4885KMO 357/4885LGALS8 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.